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ABStrACt
 Vegetarians are known to be deficient in vitamin B12, due to a lack of dietary animal products, 
which can elevate plasma total homocysteine (tHcy). Elevated total tHcy can render vegetarians 
susceptible to cardiovascular disease (CVD).There are a limited number of published studies 
in relation to the efficacy of methylcobalamin to normalise plasma tHcy of vitamin B12 deficient 
vegetarians.The primary objective of the present study was to explore the relationship between 
supplementary oral methylcobalamin and levels of tHcy of vitamin B12 deficient vegetarians; to reduce 
the risk of developing primary CVD. A randomised double blind placebo controlled pilot study was 
conducted to monitor and analyse baseline and post treatment levels of plasma tHcy, 49 volunteer 
vegetarians were recruited to participate in this study. Statistical analysis employing SPSS software 
indicated that methylcobalamin reduced mean baseline plasma tHcy of 15.5 µmolL-1 (n=39) to a 
mean plasma tHcy level of 8.4 µmolL-1  (P < 0.001). In a second group that contained details of ten 
withdrawn participants, which was conducted on an ‘Intention to Treat’ (ITT) basis, indicated that 
methylcobalamin was shown to be reduced from a mean baseline plasma tHcy of 14.7 µmolL-1(n=49) 
to a mean plasma tHcy level of 9.1 µmolL-1 (P < 0.001).The findings of the study have the potential 
to alert vegetarians of the possible risk of becoming vitamin B12 deficient, and to help avoid the 
risk of developing homocysteine related CVD. The quality data obtained in the study will allow an 
accurate sample size to be calculated for a future definite clinical study.
Key words: Hyperhomocysteinemia, vitamin B12, lactovegetarian,
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iNtrODuCtiON
 A recent systematic review and meta-
analysis1 demonstrated that vegetarians have higher 
levels of plasma tHcy and lower levels of serum 
vitamin B12 than omnivores, brought about by a lack 
of dietary animal products.
 Hyperhomocysteinemia {plasma tHcy level 
>15 µmolL-1as defined by2} has been shown to be 
linked with chronic medical conditions including 
cardiovascular disease (CVD)3, 4. Other studies 
have shown that coronary heart disease (CHD) 
is linked to homocysteine concentrations with a 
substantial risk occurring at  >10 µmolL-1 plasma 
tHcy5, 6. Furthermore, each 5 µmolL-1 increase in 
plasma tHcy is associated with an approximate 20% 
increased risk of CHD events3, 4, irrespective of diet. 
Using epidemiologic and clinical data, it has been 
suggested7 that elevated plasma tHcy is a risk factor 
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in 82.8% of the CVD conditions examined. From 
these studies 71.4% of the reported CVD conditions 
showed that plasma tHcy levels can be employed as 
a biomarker for the risk of developing CVD7. 
 Obersby et al7 have suggested that normal 
levels of plasma tHcy need to be maintained, as a 
precaution to avoid increasing the risk of developing 
or exacerbating CVD. 
 Methylcobalamin is the only form of 
vitamin B12 that contains a methyl group, and as 
a consequence is the only form of vitamin B12 that 
can directly reduce homocysteine8.
 The other forms of vitamin B12 (i.e. 
cyanocobalamin – artificially synthesised and 
widely used in supplements and fortification 
of food and beverages, hydroxocobalamin and 
adenosylcobalamin) on entry to the bloodstream 
must be converted in the body to methylcobalamin 
before they can be utilised in the folate cycle for 
remethylation of homocysteine  to methionine9, 10. 
This conversion process is necessary to maintain 
non-harmful levels of homocysteine, and in the 
case of cyanocobalamin may take from four to nine 
weeks11, assuming that there is no disruption by 
genetic factors, age related issues and metabolic 
problems1. 
 In order to test the hypothesis that 
supplementary methylcobalamin can normalise 
elevated plasma tHcy of vitamin B12 deficient 
vegetarians, a clinical trial was therefore needed. 
However, it is highly unlikely that an accurate 
calculation of the sample size of a clinical trial could 
be made unless it was based on existing strong 
evidence12, 13. The calculation of the sample size 
required to reject the null hypothesis (H0) needs to 
be based on evidence from previous studies of the 
difference likely to be found between experimental 
and control groups. The paucity of published data in 
relation to this is reflected by the fact that just one 
published study by yajnik et al14 could be located 
that tested the effectiveness of methylcobalamin 
to lower plasma tHcy in female Indian vegetarians. 
However, this was a proof of principle (POP) study. 
The duration of the study was just six weeks 
which may be too short to achieve the full effect of 
methylcobalamin supplementation. Furthermore, the 
dose size of 500µg taken every alternate day may 
not be sufficient to normalise the elevated plasma 
tHcy of vitamin B12 deficient lactovegetarians. This 
assertion is supported by the results shown within 
Table 2 of the study by yajnik et al (i.e. mean baseline 
18.4µmolL-1 to mean post treatment 13.4µmolL-1). 
These authors cited a study by Kwok et al15 which 
was specifically aimed at showing that vitamin 
B12 supplementation improves arterial functions 
in vegetarians with subnormal vitamin B12 status. 
This study was a placebo controlled crossover trial 
with vitamin B12 (500µg/day) taken over twelve 
weeks with ten weeks washout, followed by a 
further 24 weeks of vitamin B12 treatment  However, 
the type of vitamin B12 employed and how it was 
administered was undisclosed. The results of that 
study demonstrated a reduction in plasma tHcy, but 
vitamin B12 did not normalise the level of plasma 
tHcy (i.e. mean 16.7µmolL-1 at baseline to a mean 
11.3µmolL-1 following treatment).  The conflicting 
findings from this study could be a result of the 
particular rout of administration of vitamin B12 or the 
relatively short washout period of the ten weeks16. 
 Both the yajnik et al and Kwok et al 
studies failed to normalise homocysteine levels to 
< 10µmolL-15, 6.
MAtEriAlS AND MEtHODS
 The investigation reported in this paper is 
the first clinical pilot study to effectively explore the 
normalisation of elevated plasma tHcy of vegetarians 
by the direct intervention of oral methylcobalamin.
Ethical consideration
 The clinical pilot study was conducted 
according to the guidelines laid down in the 
Declaration of Helsinki17 and all procedures involving 
human subjects were approved by the University 
of West London Research Scrutiny & Ethics Sub-
Committee. Written informed consent was obtained 
from all subjects. 
registration
 The clinical pilot study was registered with 
ClinicalTrials.gov Protocol Registration System 08 
June 2012 and allocated the registration number 
NCT01661309.
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Participants
 Over the period July 2012 to December 
2013 a total of 49 volunteers living in the UK were 
recruited via the Vegetarian Society and the Vegan 
Society, and who had been practicing vegetarianism 
for  >3 years were approved to participate in the 
clinical pilot study. These subjects comprised 
lactovegetarians (LV), lactoovovegetarians (LOV) 
and vegans.  In our study LVs and LOVs were treated 
as one group, since there is no nutritional detrimental 
difference. Whilst LOVs consume eggs that contain 
traces of vitamin B12, they also contain vitamin 
B12 cobamides that block absorption of the actual 
vitamin B12 and increase the body’s need for this 
nutrient18.
inclusion criteria
 All participants of the study successfully 
completed a diet, supplements & medication, medical 
history and lifestyle confidential questionnaire and 
fulfilled the following criteria: Have a measured 
plasma tHcy of ≥ 10 µmolL-1, aged between 18 and 
65 years old, not participating in a weight reducing 
diet, not consuming regularly supplementary vitamin 
B12  > 10µg/day, not suffering from pernicious 
anaemia or other conditions resulting in vitamin 
B12 deficiency, not previously undergone bowel 
surgery or suffered from gastrointestinal disease, 
not pregnant, lactating or trying to conceive, a 
non-smoker, not consuming alcohol regularly (> 2 
units/day for females, > 3units/day for males); not 
consuming caffeine on a regular basis (> 4 cups/day 
of strong tea or coffee), not suffering from genetic 
metabolic disease, not suffering from renal failure, 
diabetes, thyroid disease, CVD, dementia or cancer, 
not using medications known to influence nutritional 
status and not suffering a known blood-borne 
infection (e.g. Hepatitis or HIV).
 From the 49 participants admitted to 
the study, ten either withdrew or were discounted 
for breaching the study protocol. In order to 
avoid overoptimistic estimates of the efficacy of 
methylcobalamin, statistical analysis was performed 
with the noncompliance and missing outcomes 
being excluded (n=39) and included (n=49) in the 
calculations. In the case of the inclusion of the 
withdrawn subjects (n = 49), intention to treat (ITT) 
analysis was included on the basis of using the strict 
rules of last observation carried forward (LOCF) 
technique (19). 
 The reason why the ten ITT subjects 
withdrew or were discounted from the study was: 
From the methylcobalamin group, four became 
omnivores; one failed to have a post treatment 
homocysteine test taken. From the placebo group, 
one failed to supply any food diaries; one was due 
to poor health; two disliked the treatment schedule; 
and one started taking high daily doses of vitamin 
B12. 
 The design and structure of the clinical 
pilot study was a double blind randomised placebo 
controlled trial with two arms. The participants, 
principal investigator and statistician were all 
unaware of the identity of the methylcobalamin and 
the placebo groups. 
 The subjects were randomly assigned to 
each arm, according to an Fx-115ms computer 
generated simple randomisation list. The oral 
methylcobalamin arm was an 1mg lozenge supplied 
and certified by Jarrow Formulas Inc, Los Angeles, 
USA. The rationale for choosing the dose size and 
frequency of consumption of the methylcobalamin 
was to ensure that there was an effect in the 
duration of the study, which also took into account 
any inadvertent dosage changes due to possible 
methylcobalamin instability.
 The oral placebo arm was a lozenge 
supplied and certified by Lonsdale Health Products 
Limited, Ingleton, UK. Each participant conducted a 
baseline plasma tHcy measurement by means of an 
accredited and validated blood self-sample testing kit, 
supplied by yORKTEST Laboratories Limited, york, 
UK. Each group dissolved one lozenge in the mouth, 
following a meal, every other day for sixteen weeks. 
A detailed seven day diet diary for the first and final 
weeks of the study was provided by each participant, 
which was supervised by a Nutritional Therapist. A 
post treatment homocysteine measurement was 
taken by each subject using a further self-sample 
testing kit supplied by yORKTEST. 
 The lozenge type of methylcobalamin 
dissolved in the mouth was preferred over a 
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swallowed whole tablet because it has been shown 
that vitamin B12 not dissolved in the mouth can be up 
to 88% mal-absorbed (20), due to the lack of R-binder 
mostly obtained from saliva, which is required to start 
the absorption process.
Data collection and distribution of lozenges
1) Each participant was allocated an Fx-115ms 
computer generated randomised code number.
2) Distribution of the lozenges by the study supervisor 
was in two containers each holding 28 lozenges of 
either type A or type B. 
3) Participants, Principal Investigator and Statistician 
were unaware which arm of the study the participants 
belong to, and to the identity of lozenges A & B.
4)  Compliance was checked by counting unused 
lozenges following the return of the containers.
 The analysis of the outcome of the study 
took place at the University of West London, UK, 
from the supervised diet diaries provided by the 
participants, and plasma tHcy measurements 
certified by yORKTEST, on an ‘ongoing’ basis. A 
pictorial representation of the clinical pilot study is 
presented in Figure 1.
Homocysteine assay
 The yORKTEST self-sample system 
enables immediate separation of blood plasma, so 
that a finger prick blood sample can be collected 
using a sterilised lancet. The sample is taken on 
arising in the morning, following an overnight fast. 
The device immediately separates the blood cells 
and collects the plasma in a collection disc. The 
sample is returned by post, which  would be received 
by yORKTEST well within the stability life of the 
returned sample, which is up to ten days , even 
when stored at 37oC (21). yORKTEST have patented 
this system and hold accreditation to the relevant 
EC Directives.
Statistical analysis
 Statistical analysis of the results was 
performed with IBM Corp SPSS software, version 21. 
A ‘Paired Samples t Test’ was performed for changes 
in plasma tHcy with the null hypothesis (H0) being 
defined as ‘there will be no change in plasma tHcy 
following treatment’. H0 was rejected if the change 
in plasma tHcy was significantly different from zero, 
but accepted if it was not significantly different from 
zero. 
 Baseline and post treatment mean, 
SD, P and CI95% values of plasma tHcy for the 
methylcobalamin and placebo groups for participants 
who completed the study (n=39) and which contained 
the ITT subjects were also tabulated.
 Also, following analysis of the diet diaries of 
the participants who completed the pilot study (n=39) 
the mean and SD of daily intakes of nutrients which 
are involved in the bio-regulation of homocysteine 
levels were calculated for the first and final weeks 
of the study and compared with RDA and daily 
adequate intake (AI) values. In view of the fact that 
the generation of homocysteine is totally dependent 
Fig. 1: Pictorial representation of  randomised double blind, 
placebo controlled, clinical pilot  study.
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table 1: Socio demographic characteristics of clinical pilot study participants
Socio demographic                              Methylcobalamin group                            Placebo group  
characteristics n=25 Mean SD 95% Ci n=24 Mean SD 95% Ci         
Age (years) 
Male  53.4 13.2 (43.7, 63.2)  48.2 15 (36.2, 60.2) 
Female  43.4 13.8 (37.1, 49.8)  44.7 14.9 (37.8, 51.6) 
Gender 
Males 5 (20%)    6 (25%)     
Female 20 (80%)    18 (75%)    
Classification 
Lactovegetarian 2 (8%)    1 (4.2%) 
Lactoovovegetarian 14 (56%)    12  (50%)    
Vegan 9 (36%)    11 (45.8%)   
table 2: Comparison of mean values of baseline and post treatment of plasma tHcy, for 
participants who completed the clinical pilot study (n=39) and which contained the itt 
subjects (n=49)
lozenge type  Baseline              Post treatment 
 n Mean SD Mean SD P (2-tailed)  
Completed study
Methylcobalamin 
Homocysteine (µmolL-1) 20 15.5 3.7 8.4 3.1 < 0.001
Placebo
Homocysteine  (µmolL-1) 19 13.7 2.6 12.5 4.5 0.16   
itt 
Methylcobalamin 
Homocysteine (µmolL-1) 25 14.7 3.7 9.1 3.1 < 0.001
Placebo 
Homocysteine  (µmolL-1) 24 14.1 2.8 12.9 4.5 0.54
on the amino acid methionine (22), the methionine 
content of the participants’ diet diaries was compared 
with the baseline plasma tHcy, to establish if a 
correlation exists.
rESultS
 The socio demographic characteristics 
of age, gender, and vegetarian classification of 
the participants of the pilot study are presented in 
Table 1.  The comparison of mean values and SD’s 
of baseline and post treatment values of plasma 
tHcy, for subjects who completed the pilot study and 
the group containing ITT subjects are presented in 
Table 2.  There were no reported adverse events 
from the treatments reported by the participants 
who completed the study.  Comparison of the 
nutrients which are involved in the bio-regulation 
of homocysteine levels and RDA and AI values are 
presented in Table 4A and Table 4B.
 In Table 4A and Table 4B, it was deemed 
unnecessary to conduct a test of significance for 
mean nutrient levels (except vitamin B12) that are 
equal to or exceeded the RDA. With regard to the 
mean intake of TMG, a point value for the AI was 
taken as 750mg. All groups with the exception of 
male vegans (due to small sample) were found to 
be all significantly less than the AI, for both the first 
and final seven days of the diet diaries. The choline 
mean intake for all groups with the exception of male 
vegans (due to small sample) was found to be all 
significantly less than the AI for both the first and 
final seven days of the diet diaries.
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table 3: Paired samples t test, change in plasma tHcy, for participants who completed the 
pilot study (n=39) and the group containing ‘intention to treat’ subjects (n=49), with in all 
cases test value = 0.
lozenge type df P (2-tailed) Mean 95% Confidence
and test (á = 0.05) difference interval
Change in plasma total homocysteine 
(µmol/l) Completed study (n=39)
Methylcobalamin 19 0.00 -7.1 (-9.35, -4.85)
Placebo 18 0.16 -1.11 (-2.70, 0.48)
intention to treat (n=49)
Methylcobalamin 24 0.00 -5.6 (-7.78, -3.42)
Placebo 23 0.54 -1.21 (-2.6, 0.18) 
table 4A: Comparison of daily intake of nutrients and have intake of nutrients involved in the 
bio-regulation of homocysteine levels of participants who completed the clinical pilot study 
(n=39), taken from the diet diaries for the first seven days of the study. [rDAs and Ais taken from 
the institute of Medicine of the Academy of Science (23). Dietary nutrients are in accordance with 
Foods Standards Agency (24) and uSDA Agricultural research Service (25)]
                                      lactovegetarian /lactoovovegetarian             Vegan                      Adult values
Nutrient n Mean SD P(2-tailed) n Mean SD P(2-tailed) rDA Ai
Males 11    2
Vitamin B2 (mg)  1.7 0.71   1.3 0.14  1.30
Vitamin B6 (mg)  2.2 0.58   1.5 0.28  1.30
Vitamin B12 (µg)  2.0 0.49 0.031  1.0 0.65 0.208 2.40    
Folate  (µg)  533 133   402 67.9  400
Zinc (mg)  12.2 3.0   11.0 3.1  11.0
Choline (mg)  160 48.6 0.000  215 72.1 0.152 550
Trimethylglycine (mg)  142 71.6 0.000  130 17 0.012 500-1000      
Females 14    12
Vitamin B2  (mg)  1.3 0.68   1.3 0.92  1.10                   
 Vitamin B6 (mg)  1.5 0.83   1.4 0.73  1.30
Vitamin B12 (µg)  3.4 0.41 0.000  0.7 0.33 0.59 2.40
Folate  (µg)  406 201   420 210  400
Zinc (mg)  12.4 2.5   14.0 2.9  8.0
Choline (mg)  227 56.3 0.000  180 52.3 0.000 425
Trimethylglycine (mg)  268 28.1 0.000  247 42.1 0.000 500-1000
 The mean vitamin B12 for the first and 
final days of the diet diaries, female LV-LOVs are 
significantly higher than the RDA, whilst both 
genders of vegans are significantly less than the 
RDA. This also applies to male LV-LOVs for the first 
seven days of diet diaries.
 Only female LV-LOVs for the first seven 
days of the diet diaries contain mean levels of vitamin 
B12 that is significantly higher than the RDA, whilst 
both genders of LV-LOVs significantly meet the 
RDA for the final seven days of the diet diaries. It 
was observed from the confidential questionnaire, 
completed by all applicants that 53% (n = 34) were 
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table 4B: Comparison of daily intake of nutrients and have intake of nutrients involved in the 
bio-regulation of homocysteine levels of participants who completed the clinical pilot study 
(n=39), taken from the diet diaries for the final seven days of the study.  [rDAs and Ais taken from 
the institute of Medicine of the Academy of Science (23). Dietary nutrients are in accordance with 
Foods Standards Agency (24) and uSDA Agricultural research Service (25)]
                                      lactovegetarian/lactoovovegetarian              Vegan                  Adult values        
Nutrient n Mean SD P(2-tailed) n Mean  SD P(2-tailed) rDA Ai      
Males 11    2
Vitamin B2 (mg)  2.5 0.32   1.3 0.14  1.30
Vitamin B6 (mg)  1.4 0.68   2.1 0.99  1.30
Vitamin B12 (µg)  3.0 0.3 0.000  1.6 0.57 0.68 2.40
Folate  (µg)  489 97   448 139  400
Zinc (mg)  11.2 2.1   14 1.4  11.0
Choline (mg)  234 51 0.000  195 12.7 0.025 550
Trimethylglycine (mg)  130 51.7 0.000  166 39.6 0.030 500-1000
Females 14    12
Vitamin B2  (mg)  1.3 0.84   1.3 0.77  1.10
Vitamin B6 (mg)  1.3 0.97   2.2 0.74  1.30
Vitamin B12 (µg)  3.0 0.68 0.000  1.7 0.48 0.038 2.40
Folate  (µg)  408 221   448 215  400
Zinc (mg)  8.4 2.3   16.6 0.99  8.0
Choline (mg)  201 46.9 0.000  186 54.4 0.000 425
Trimethylglycine (mg)  208 85.4 0.000  199 86.3 0.000 500-1000
Fig. 2: Correlation between baseline plasma tHcy and mean dietary methionine intake, for vitamin 
B12 deficient vegetarians from the intervention group, who completed the clinical pilot study
oblivious to the potential detrimental effect to health 
of elevated plasma tHcy, as a result of a deficiency 
of vitamin B12 in vegetarian diets. 
 Analysis of the diet diaries of the participants 
who completed the study strongly indicate (R2 = 0.79) 
that there exists a positive correlation between 
baseline plasma tHcy and mean dietary methionine 
intake of the form y=A.l
n
(X)-C (see Figure 2) of 
vegetarian deficient vegetarians. This dispersed 
following methylcobalamin intervention due to the 
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normalisation of participants’ plasma tHcy.
DiSCuSSiON
 The statistical results presented in Table 2 
demonstrate that methylcobalamin reduced mean 
baseline plasma tHcy level of 15.5µmolL-1 (n=39) 
to a post treatment plasma tHcy level of 8.4µmolL-1 
(P<0.001). In the ITT group this also demonstrated 
that methylcobalamin reduced a mean baseline 
plasma tHcy level of 14µmolL-1 (n=49) to a mean 
post treatment plasma tHcy level of 9.1µmolL-1 
(P<0.001). Both sets of results indicate that 
methylcobalamin normalises plasma tHcy levels, 
whereas, the placebo failed to achieve this. The 
above results are supported by the results presented 
in Table 3, which demonstrates that for subjects that 
completed the trial (n=39) and the ITT group (n=49) 
H0 can be rejected for the methylcobalamin group, 
since P<0.05 and CI95% does not pass through 
zero. In both the placebo groups H0 is accepted, 
since P>0.05 and CI95% passes through zero. No 
previously published trials were found that could be 
directly compared with the outcomes of the present 
study.  The very positive effect of methylcobalamin 
on lowering plasma tHcy leads to the conclusion 
that methylcobalamin can even at this pilot study 
stage be recommended as a food supplement for 
all categories of vegetarianism, to help maintain 
homocysteine at non-harmful levels. 
 Since methylcobalamin was administered 
in the lozenge form, this ensured that absorption 
took place by mediated intrinsic factor, non-intrinsic 
mediated diffusion and sublingual intake. This is 
particularly advantageous to individuals who cannot 
readily absorb vitamin B12 by mediated intrinsic 
factor due to autoimmune problems, resulting in 
partial or full pernicious anaemia (26-28). 
 Table 4.9A and Table 4.9B illustrates that 
those subjects completing the study consumed at 
least the RDA and AIs range of mean values of 
nutrients that can influence homocysteine reduction 
with the exception of vitamin B12 for vegans and 
male LV-LOVs and both genders for LV-LOV and 
vegans for choline and trimethylglycine (TMG). 
However, the TMG reaction for the remethylation of 
homocysteine, can only take place in the liver and 
kidney of human beings as the enzyme involved, 
betaine homocysteine methyltransferase, is not 
present in other organs of the body (29). The influence 
on elevated plasma tHcy is therefore considered to 
be minimal in the TMG reaction.
 Vitamin B12 was not measured since there 
are no accredited or validated assays available that 
have sufficient sensitivity and specificity to measure 
methylcobalamin that has been absorbed into cells. 
Some participants independently arranged for their 
physician to have their vitamin B12 status measured. 
In most cases the results indicated that their vitamin 
B12 status was normal i.e. > 150pmolL-1 (30), yet their 
homocysteine level was found to be elevated. This is 
explained by the fact that NHS vitamin B12 assays 
measure total serum vitamin B12 (31).  The standard 
NHS vitamin B12 assay measures total plasma 
cyanocobalamin, following chemical modification 
of the other forms of cobalamin to cyanocobalamin 
by potassium cyanide. The procedure renders the 
assay impossible to identify each fraction of vitamin 
B12 being measured. As a consequence, it can be 
reasonably deduced that under these circumstances 
these participants were actually methylcobalamin 
deficient leading to a rise in plasma homocysteine 
levels.
 Verification of participant methylcobalamin 
deficiency is strongly indicated by the fact that these 
participant plasma tHcy was normalised (i.e. < 
10µmolL-1) by the intervention of methylcobalamin 
during their participation in the present clinical pilot 
study.
 It is very clear from the results of the clinical 
pilot study and analysis of the participants’ diet diaries 
which show that the diets are rich in the homocysteine 
lowering nutrients. In addition, participants exhibited 
subnormal levels of methylcobalamin, resulting in 
elevated plasma tHcy, which according to the results 
of the study have been normalised, probably due 
to: The type of intervention employed, dose size, 
duration of treatment,  methylcobalamin supplement 
dissolved in the mouth and therefore mixed with 
saliva. 
 In conclusion, the primary objective was 
successful since the results of this study strongly 
suggest that supplementary methylcobalamin will 
normalise elevated plasma tHcy of vitamin B12 
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deficient vegetarians provided that they are not 
deficient in other bio-regulation of homocysteine 
nutrients and enzymes. According to Huang et al 
(32)
 vitamin B6 and folate have little or no effect on 
plasma tHcy concentration when individuals have 
adequate dietary vitamin B6 and folate intakes. 
Furthermore, it will allow an accurate sample size 
to be calculated for a further definitive clinical trial. 
Analyses indicate that the RDA for vitamin B12 
maybe too low. This supports previous research (33), 
which demonstrates that doses of vitamin B12 of 
≥ 6µg/day appear to be sufficient to maintain a 
steady-state concentration of serum vitamin B12.
 It was discovered that a logarithmic 
relationship exists between baseline plasma tHcy 
of vitamin B12 deficient vegetarians and dietary 
methionine, which no longer exists, following 
intervention by methylcobalamin. 
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